Subcutaneous injections of AV513 improve the clot dynamics in AAV-hemophilia A dogs. In a dose-escalation study, plasma prepared from AAV-hemophilia A dogs before dosing and at the end of each dosing period were evaluated for clotting in a TEG assay. TEG R time represents the time required to initiate a 2-mm clot. (A) Progressive change in TEG R times of individual animals during the treatment period is plotted. (B) A TEG R time averaged from 3 dogs at each dose is represented as a bar graph with error bars representing SD. (*P = .017, **P = .019 compared with baseline values.) (C) TEG angle represents the rate of fibrin formation, P values at 0.5, 1.0, and 1.5 mg/kg dose are .04, .002, and .001, respectively. (D) TEG MA represents clot strength, P values at 0.5, 1.0, and 1.5 mg/kg dose are .03, .02, and .015, respectively. Gloria (■), Morag (▲), and Angus (◆). The boxed area in the graphs represents the clot dynamics values for normal plasma.